ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1853

Rheumatoid Arthritis Patients’ Experiences of Medication Side Effects and Subsequent Decision Making about Medications

Yomei Shaw1, Ilinca D. Metes2, Susan L. Zickmund3, Dawn McBride2, Kelly A. Reckley2, Stephen R. Wisniewski4, Larry W. Moreland2, Mark S. Roberts1 and Marc C. Levesque2, 1Department of Health Policy and Management, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, 2Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, 3Division of General Internal Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, 4Epidemiology, University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Adverse events, health behaviors, medication side effects, patient preferences and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Title: Epidemiology and Health Services Research: Rheumatic Disease Pharmacoepidemiology

Session Type: Abstract Submissions (ACR)

Background/Purpose:  Medication adherence in rheumatoid arthritis (RA) patients can be influenced by their previous experiences with medication side effects.  Negative experiences may lead patients to become fearful towards medications, increasing rates of non-adherence and rejection of physician recommendations to add medication therapy.  To better understand how patients’ experiences of adverse drug reactions affect perceptions of medication risk and subsequent decisions to take recommended medications, we conducted an analysis of patient narratives of their experiences with adverse drug reactions due to medications for RA.  Our goal was to describe features of RA patients’ experiences of medication side effects, and to compare narratives of patients who self-report discontinuing medications on their own or rejecting physician recommendations for medications (‘Non-adherent’ group) with narratives of patients who do not (‘Adherent’ group).

Methods:  A qualitative analysis was conducted of transcripts from semi-structured interviews with 20 RA patients.  Interviews were from a pilot study testing patient education materials for usage in the RA Comparative Effectiveness Research (RACER) registry (n = 1,000).  Subjects were recruited from RACER enrollees treated at a participating clinic. During interviews, subjects were asked whether they had ever experienced side effects due to their medications for RA, and if so, to describe the side effects.  Comments of all subjects describing any experiences of side effects were analyzed.  A coding scheme was developed to index statements about: 1) medications in general, 2) the side effects experienced and relevant medications, 3) the patient-provider relationship, and 4) RA and treatment related information.  The first 2 authors coded the interview transcripts separately, then discussed and reached a consensus on assignment of codes for each transcript. Codes for patients in the Non-adherent group were compared to the Adherent group.

Results:  Fourteen of 20 patients reported side effects.  The inter-observer agreement was high (mean kappa = 0.90).  Among the 14 subjects with side effects, subjects in the Non-adherent group (n = 6) and Adherent group (n = 8) reported a similar mean number of side effects which they perceived as important (2.83 vs. 2.13) and non-important (0.67 vs. 1.25). However, patients in the Non-adherent group were more likely than patients in the Adherent group to discuss fear (66.7% vs. 12.5%), unacceptability of side effects (66.7% vs. 25%), unsatisfactory resolution of side effects (66.7% vs. 25%), and negative aspects of medications (83.3% vs. 25%).

Conclusion:  Fear, viewing side effects as unacceptable, dissatisfaction with how side effects were resolved, and negative perceptions of medications played a more central role in the experiences of patients who discontinued medications on their own or rejected physician recommendations, compared to patients who did not.  This suggests that interventions to address these patient concerns may be critical for improving patient adherence to medications.


Disclosure:

Y. Shaw,
None;

I. D. Metes,
None;

S. L. Zickmund,
None;

D. McBride,
None;

K. A. Reckley,
None;

S. R. Wisniewski,
None;

L. W. Moreland,
None;

M. S. Roberts,
None;

M. C. Levesque,
None.

  • Tweet
  • Email
  • Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/rheumatoid-arthritis-patients-experiences-of-medication-side-effects-and-subsequent-decision-making-about-medications/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology